Hong Lili, Guo Zhi, Yu Haipeng, Li Baoguo, Si Tongguo, Liu Changfu
Department of Interventional Therapy, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China.
Department of Interventional Therapy, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China. Email:
Zhonghua Yi Xue Za Zhi. 2014 Jul 1;94(25):1929-32.
To evaluate the efficacy and safety of the regimen of low-dose high intensity focused ultra-sound (HIFU) plus S-1 and oxaliplatin (SOX) in the treatment of metastatic colorectal cancer patients with pelvic masses.
A total of 46 patients with metastatic colorectal cancer were recruited and divided into 2 groups: Twenty patients received concurrent HIFU plus S-1 and oxaliplatin (SOX) while another 26 patients SOX alone. The baseline characteristics, progressive-free survival, overall survival time and adverse events were retrospectively analyzed.
The median PFS was 11.2 months (95% CI 9.8-12.7) in the HIFU+SOX group and 7.1 months (95% CI 5.8-8.4) in the SOX group (P = 0.003). And the overall survival time in two groups were 21.9 months (95% CI 18.0-25.9) and 16.9 months (95%CI 14.1-19.6) (P = 0.072) respectively. Major toxic effects included grade 3/4 neutropenia (15%), anemia (10%), thrombocytopenia (10%), diarrhea (15%) and hand-foot syndrome (10%) in the HIFU+SOX group. And it showed no statistically significant differences with the SOX group.
The combined regimen of HIFU and SOX is effective and well-tolerated in patients of late-stage colorectal cancer with pelvic masses.
评估低剂量高强度聚焦超声（HIFU）联合S-1与奥沙利铂（SOX）方案治疗伴有盆腔肿块的转移性结直肠癌患者的疗效和安全性。
共招募46例转移性结直肠癌患者，分为2组：20例患者接受HIFU联合S-1与奥沙利铂（SOX）治疗，另外26例患者仅接受SOX治疗。回顾性分析患者的基线特征、无进展生存期、总生存时间和不良事件。
HIFU+SOX组的中位无进展生存期为11.2个月（95%CI 9.8-12.7），SOX组为7.1个月（95%CI 5.8-8.4）（P=0.003）。两组的总生存时间分别为21.9个月（95%CI 18.0-25.9）和16.9个月（95%CI 14.1-19.6）（P=0.072）。HIFU+SOX组的主要毒副作用包括3/4级中性粒细胞减少（15%）、贫血（10%）、血小板减少（10%）、腹泻（15%）和手足综合征（10%）。与SOX组相比，差异无统计学意义。
HIFU与SOX联合方案治疗伴有盆腔肿块的晚期结直肠癌患者有效且耐受性良好。
